论文部分内容阅读
目的观察乙型肝炎肝硬化代偿期使用恩替卡韦联合疏肝解毒汤治疗疗效分析。方法将在我院就诊,近期(2012年6月至2015年6月时期)门诊及住院患者,收治确定诊断的210例乙型肝炎肝硬化代偿期患者,随机将其分成三组,分别为常规组、对照组、治疗组,每组70名患者。常规组采用阿德福韦酯片治疗,对照组采用恩替卡韦片治疗,治疗组采用恩替卡韦片联合疏肝解毒汤治疗。将三组化验室指标及临床疗效对比分析。结果疗程结束后,从肝功能及肝纤维化指标来看,治疗组优于对照组优于常规组。临床总有效率由高到低依次为治疗组,对照组,常规组。结论恩替卡韦联合疏肝解毒汤可有效治疗乙型肝炎肝硬化代偿期患者,临床效果明显,值得推广。
Objective To observe the therapeutic effect of entecavir combined with Shugan Jiedu Decoction in the decompensation of hepatitis B cirrhosis. Methods A total of 210 outpatients and inpatients admitted to our hospital from June 2012 to June 2015 were enrolled in this study. 210 confirmed cases of hepatitis B cirrhosis were randomly divided into three groups: Conventional group, control group, treatment group, each group of 70 patients. The conventional group was treated with adefovir dipivoxil, the control group was treated with entecavir tablets, and the treatment group was treated with entecavir tablets combined with Shugan Jiedu Decoction. Three sets of laboratory indexes and clinical efficacy comparison analysis. Results After treatment, from the liver function and liver fibrosis indicators, the treatment group was superior to the control group than the conventional group. The total effective rate from high to low order treatment group, control group, conventional group. Conclusion Entecavir combined with Shugan Jiedu Decoction can effectively treat patients with decompensated hepatitis B due to its clinical effect and is worthy of promotion.